Seventy-four percent of patients were on Pneumocystis jirovecii (PJ) prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX), and 53 (8%) patients with a known risk of hepatitis B reactivation (HBc+ and, or HBsAg+) received lamivudine. Here, PPIB is linked to hepatitis A virus infection.